Bolt Biotherapeutics (BOLT)
(Real Time Quote from BATS)
$0.57 USD
-0.03 (-4.62%)
Updated Sep 25, 2024 01:56 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Bolt Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 102 | 169 | 186 | 23 | 35 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 3 | 3 | 1 |
Total Current Assets | 106 | 173 | 189 | 25 | 36 |
Net Property & Equipment | 5 | 6 | 6 | 4 | 1 |
Investments & Advances | 26 | 24 | 85 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 2 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 3 | 3 | 2 | 1 |
Total Assets | 160 | 228 | 308 | 47 | 48 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 4 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 15 | 12 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 3 | 2 | 1 |
Total Current Liabilities | 20 | 23 | 21 | 11 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 9 | 13 | 14 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 17 | 20 | 22 | 9 | 7 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 25 | 0 |
Total Liabilities | 47 | 56 | 58 | 46 | 17 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 105 | 78 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 477 | 468 | 457 | 3 | 2 |
Retained Earnings | -364 | -295 | -207 | -108 | -48 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 113 | 172 | 250 | 0 | 32 |
Total Liabilities & Shareholder's Equity | 160 | 228 | 308 | 47 | 48 |
Total Common Equity | 113 | 172 | 250 | -105 | -46 |
Shares Outstanding | 37.90 | 37.60 | 37.20 | NA | NA |
Book Value Per Share | 2.97 | 4.56 | 6.72 | 0.00 | 0.00 |
Fiscal Year End for Bolt Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 74 | 91 | 102 | 120 | 126 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 4 | 6 | 5 |
Total Current Assets | 77 | 95 | 106 | 125 | 131 |
Net Property & Equipment | 4 | 5 | 5 | 5 | 6 |
Investments & Advances | 24 | 21 | 26 | 22 | 31 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 4 | 4 | 3 | 3 |
Total Assets | 124 | 143 | 160 | 175 | 191 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 10 | 12 | 10 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 18 | 17 | 20 | 19 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 5 | 9 | 10 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 16 | 17 | 17 | 18 | 19 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 39 | 47 | 47 | 49 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 482 | 479 | 477 | 475 | 472 |
Retained Earnings | -396 | -375 | -364 | -346 | -330 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 86 | 104 | 113 | 128 | 142 |
Total Liabilities & Shareholder's Equity | 124 | 143 | 160 | 175 | 191 |
Total Common Equity | 86 | 104 | 113 | 128 | 142 |
Shares Outstanding | 38.10 | 38.10 | 37.90 | 37.90 | 37.80 |
Book Value Per Share | 2.25 | 2.73 | 2.97 | 3.38 | 3.76 |